Virginia Retirement Systems ET AL Invests $459,000 in Opko Health Inc. (OPK)
Virginia Retirement Systems ET AL acquired a new position in shares of Opko Health Inc. (NYSE:OPK) during the second quarter, Holdings Channel reports. The institutional investor acquired 49,100 shares of the company’s stock, valued at approximately $459,000.
Several other large investors have also modified their holdings of OPK. Commonwealth Equity Services Inc increased its position in shares of Opko Health by 4.6% in the first quarter. Commonwealth Equity Services Inc now owns 56,358 shares of the company’s stock valued at $586,000 after buying an additional 2,462 shares in the last quarter. Aperio Group LLC increased its position in shares of Opko Health by 67.1% in the first quarter. Aperio Group LLC now owns 63,042 shares of the company’s stock valued at $655,000 after buying an additional 25,312 shares in the last quarter. Virginia Retirement System purchased a new position in shares of Opko Health during the first quarter valued at $510,000. Teachers Advisors Inc. increased its position in shares of Opko Health by 3.6% in the first quarter. Teachers Advisors Inc. now owns 325,172 shares of the company’s stock valued at $3,379,000 after buying an additional 11,403 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Opko Health by 239.6% in the first quarter. BlackRock Inc. now owns 36,005 shares of the company’s stock valued at $375,000 after buying an additional 25,403 shares in the last quarter.
Opko Health Inc. (NYSE:OPK) opened at 10.43 on Friday. The company has a 50 day moving average of $10.06 and a 200-day moving average of $10.13. Opko Health Inc. has a one year low of $7.12 and a one year high of $11.85. The firm has a market cap of $5.74 billion and a PE ratio of 43.64.
Opko Health (NYSE:OPK) last posted its quarterly earnings data on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The firm had revenue of $357.10 million for the quarter, compared to analysts’ expectations of $324.11 million. The company’s revenue for the quarter was up 742.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.09) EPS. On average, equities research analysts predict that Opko Health Inc. will post ($0.05) earnings per share for the current year.
Several research analysts recently weighed in on OPK shares. JPMorgan Chase & Co. set a $14.00 target price on shares of Opko Health and gave the stock a “buy” rating in a report on Tuesday, August 9th. Standpoint Research upped their target price on shares of Opko Health from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, June 21st. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Opko Health in a report on Thursday, June 16th. Jefferies Group reaffirmed a “hold” rating and issued a $10.00 target price (down previously from $11.00) on shares of Opko Health in a report on Friday, June 17th. Finally, Deutsche Bank AG dropped their target price on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating for the company in a report on Thursday, June 16th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $13.20.
In other news, CEO Phillip Md Et Al Frost acquired 48,400 shares of the company’s stock in a transaction dated Thursday, August 25th. The shares were bought at an average price of $9.06 per share, for a total transaction of $438,504.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $27,804,696.06. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Opko Health Company Profile
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NYSE:OPK).
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.